Skip to content

Wound Dressings For Split-Thickness Skin Graft Donor Sites in Patients Undergoing Surgery

A Comparative Study of Dressings for Split-Thickness Skin Graft Donor Sites.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01680367
Enrollment
69
Registered
2012-09-07
Start date
2008-11-30
Completion date
2010-07-31
Last updated
2016-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Perioperative/Postoperative Complications

Brief summary

This study is to determine what dressing would work best to heal and keep from hurting, the split-thickness skin graft donor site which will be done as part of the patient's surgical procedure. Currently there is a dressing that is transparent and it is placed on the wound after surgery and wrapped with gauze and an elastic bandage. Two days after the surgery the gauze and elastic bandages are removed and the area is left with the transparent dressing. Sometimes the dressing needs to be changed because it leaks. On the fifth day this dressing is removed and the wound is left open to air. The dressing researchers are studying is a dressing that has been used for different types of wounds, as well as this type of wound. It is applied in the same manner; however, it is left in place until it falls off independently, usually around post-operative (post-op) day 10.

Detailed description

PRIMARY OBJECTIVES: I. Which dressing type and technique is most effective in minimizing pain and inflammation and promoting epithelialization in patients who have had surgery which requires the use of an anterior thigh split-thickness skin graft? OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive transparent film dressing (otolaryngology service) or Xeroform petroleum gel impregnated gauze dressing (surgical oncology service) after surgery. ARM II: Patients receive native collagen wound dressing after surgery.

Interventions

Receive transparent film dressing or Xeroform petroleum gel impregnated gauze dressing

OTHERquestionnaire administration

Ancillary studies

Sponsors

Ohio State University Comprehensive Cancer Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Population of otolaryngological or surgical oncology patients experiencing an autologous split-thickness skin graft as part of their surgical procedure * Patients will have a Glasgow Coma score of 15 (or 10 with a tracheostomy) * Patient donor sites will be limited to the anterior thigh * Patients will be free of documented circulatory deficits, neuropathy, or mental illness which prohibits their ability to independently consent or respond to questions regarding pain * Patients will be able to give consent independently * Patients will be able to read and write in English

Exclusion criteria

* Patients unable to give independent consent for any reason * Skin graft donor sites other than the anterior thigh * Patients with a concurrent diagnosis of diabetes, peripheral vascular disease, and/or paresthesias or paralysis of the lower extremities * Patients who are unable to complete a self-report pain scale * Patients who are prisoners * Patients who are known active alcoholics * Patients on steroids or other medications known to affect healing

Design outcomes

Primary

MeasureTime frameDescription
Pain score ranging in value from 0 to 10Up to 14 daysInitial analyses will include two sample t-tests (or a nonparametric equivalent, if more appropriate) for each day to compare the mean pain scores for each treatment group. The pain score will be evaluated using multiple linear regression, while multiple logistic or polytomous regression will be used for the categorical outcomes.

Secondary

MeasureTime frameDescription
Distress checklist scoreUp to 14 daysThe specific modeling approach for the distress score will depend on the range of values obtained. Standard model building techniques will be employed and clinically important interactions between covariates and the groups will be explored.
Inflammation as measured by the Wound Assessment Inventory (WAI)Up to 14 days
Categorical epithelialization assessmentUp to 14 days

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026